1 Pascarella, G. et al. COVID-19 diagnosis and management: a comprehensive review. J. Intern. Med., doi:10.1111/joim.13091 (2020).
2 Wang, W. et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA, doi:10.1001/jama.2020.3786 (2020).
3 Pasomsub, E. et al. Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease 2019: a cross-sectional study. Clin. Microbiol. Infect., doi:10.1016/j.cmi.2020.05.001 (2020).
4 Zhao, J. et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin. Infect. Dis., doi:10.1093/cid/ciaa344 (2020).
5 Qu, J. et al. Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis., doi:10.1093/cid/ciaa489 (2020).
6 To, K. K.-W. et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. The Lancet Infectious Diseases 20, 565-574, doi:10.1016/s1473-3099(20)30196-1 (2020).
7 Jin, Y. et al. Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019. Int. J. Infect. Dis. 94, 49-52, doi:10.1016/j.ijid.2020.03.065 (2020).
8 Hsueh, P. R., Huang, L. M., Chen, P. J., Kao, C. L. & Yang, P. C. Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. Clin. Microbiol. Infect. 10, 1062-1066, doi:10.1111/j.1469-0691.2004.01009.x (2004).
9 Park, W. B. et al. Kinetics of Serologic Responses to MERS Coronavirus Infection in Humans, South Korea. Emerg. Infect. Dis. 21, 2186-2189, doi:10.3201/eid2112.151421 (2015).
10 Al Johani, S. & Hajeer, A. H. MERS-CoV diagnosis: An update. J Infect Public Health 9, 216-219, doi:10.1016/j.jiph.2016.04.005 (2016).
11 Long, Q. X. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. 26, 845-848, doi:10.1038/s41591-020-0897-1 (2020).
12 Zhang, B. et al. Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19 doi:10.1101/2020.03.12.20035048 (2020).
13 Zhang, G., Nie, S., Zhang, Z. & Zhang, Z. Longitudinal Change of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies in Patients with Coronavirus Disease 2019. J. Infect. Dis. 222, 183-188, doi:10.1093/infdis/jiaa229 (2020).
14 Zhang, J. et al. Serological detection of 2019-nCoV respond to the epidemic: A useful complement to nucleic acid testing. doi:10.1101/2020.03.04.20030916 (2020).
15 Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature, doi:10.1038/s41586-020-2349-y (2020).
16 Infantino, M. et al. Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience. J. Med. Virol., doi:10.1002/jmv.25932 (2020).
17 Rees, F., Doherty, M., Grainge, M. J., Lanyon, P. & Zhang, W. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford) 56, 1945-1961, doi:10.1093/rheumatology/kex260 (2017).
18 Danchenko, N., Satia, J. A. & Anthony, M. S. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 15, 308-318, doi:10.1191/0961203306lu2305xx (2006).
19 Zhou, F. Tracing Asymptomatic SARS-CoV-2 Carriers Among 3674 Hospital Staff. doi:https://ssrn.com/abstract=3582765 (2020).
20 Sekine, T. et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. doi:10.1101/2020.06.29.174888 (2020).
21 Qian, C. et al. Development and Multicenter Performance Evaluation of The First Fully
Automated SARS-CoV-2 IgM and IgG Immunoassays doi:10.1101/2020.04.16.20067231 (2020).